You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):控股子公司上海澤潤獲新老股東擬注資3.5億元 欲加快推進HPV疫苗臨牀研究和產業化上市進程
格隆匯 12-28 18:33

格隆匯12月28日丨沃森生物(300142.SZ)公佈,公司於2021年12月28日召開第四屆董事會第三十次會議,審議通過了《關於對控股子公司上海澤潤生物科技有限公司增資的議案》。

為保障公司控股子公司上海澤潤的未來戰略規劃實施和各項業務的健康發展,經各方友好協商,上海澤潤擬增加註冊資本並由新投資方以及上海澤潤原股東沃森生物、上海博荃以現金方式進行增資。

該次增資方將合計以現金3.50億元人民幣認繳上海澤潤新增註冊資本人民幣7374.9422萬元,其中,沃森生物以現金1億元人民幣認繳上海澤潤新增註冊資本人民幣2107.1263萬元。該次增資完成後,上海澤潤註冊資本將由人民幣10.1142億元變更為人民幣10.8517億元。

上海澤潤該次增資將引入新的投資者,滿足上海澤潤運營資金需求,進一步增強上海澤潤的抗風險能力,並可充分發揮各股東的資源優勢,加快推進上海澤潤HPV系列疫苗的臨牀研究和產業化上市進程,促進上海澤潤的健康、快速發展,有利於上海澤潤和公司的長遠發展利益,符合公司的整體發展戰略。

該次增資完成後,上海澤潤依然為公司的控股子公司,公司直接持有上海澤潤的股權比例由58.6610%變動為56.6161%。該次增資不會對公司2021年度的業績以及未來的財務狀況和經營成果產生重大影響,不會影響公司的正常生產經營活動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account